Vyvanse Pharmacokinetics (ADME): How Lisdexamfetamine Is Absorbed, Distributed, Metabolized, and Excreted

What Kind of Drug Is Vyvanse, and Why Does the Prodrug Design Matter?

Lisdexamfetamine is a lysine-amphetamine conjugate. The molecule itself does not bind dopamine or norepinephrine transporters. It produces no pharmacological effect until hydrolyzed in the body. This prodrug architecture was designed deliberately to slow the rise of active drug in plasma and reduce the sharp concentration spike that correlates with euphoria and abuse liability.

The FDA approved lisdexamfetamine dimesylate (Vyvanse, Takeda) in 2007 for ADHD and in 2015 for moderate-to-severe binge eating disorder. The full prescribing information is maintained at the FDA's drug database.

How the Prodrug Concept Limits Abuse

Because enzymatic hydrolysis in red blood cells is rate-limited, attempts to extract or concentrate lisdexamfetamine by intranasal or intravenous routes do not produce faster or higher peak d-amphetamine levels compared with the oral route. A pharmacokinetic crossover study published in CNS Drugs confirmed that intravenous lisdexamfetamine generated a slower d-amphetamine Tmax than intravenous d-amphetamine itself, supporting the abuse-deterrent rationale. Jasinski and Krishnan (2009) documented this in a controlled human abuse-potential study.

Mechanism of Action of the Released d-Amphetamine

Once freed from the lysine carrier, d-amphetamine enters presynaptic terminals in the striatum and prefrontal cortex. It reverses the vesicular monoamine transporter 2 (VMAT2), flooding the cytoplasm with dopamine and norepinephrine, then reverses the direction of the dopamine transporter (DAT) and norepinephrine transporter (NET), driving those catecholamines into the synapse. The net result is sustained elevation of synaptic dopamine and norepinephrine in circuits governing attention and impulse control. Sulzer et al. (2005) in the Journal of Neurochemistry provides a detailed mechanistic account.

Absorption: How Vyvanse Enters the Body

Lisdexamfetamine is rapidly absorbed from the gastrointestinal tract after oral administration. The intact prodrug reaches peak plasma concentrations (Tmax) in approximately 1 hour. Food does not prevent absorption, though a high-fat meal delays lisdexamfetamine Tmax by roughly 1 hour and d-amphetamine Tmax by approximately 1 hour as well, without meaningfully changing total exposure (AUC). This is documented in the FDA-reviewed clinical pharmacology section of the NDA.

Oral Bioavailability

The absolute oral bioavailability of lisdexamfetamine has not been directly measured against an intravenous reference in typical clinical studies, because the intravenous form is not a licensed product. However, urinary recovery data showing approximately 96% of radioactivity excreted after an oral dose indicates high systemic absorption. The Vyvanse package insert references this recovery figure.

First-Pass Considerations

Lisdexamfetamine does not undergo meaningful hepatic first-pass metabolism as a prodrug. The GI tract and liver do not substantially hydrolyze the lysine-amphetamine bond. Conversion happens predominantly after the intact prodrug reaches the systemic circulation and contacts red blood cell peptidases. This separates lisdexamfetamine from traditional amphetamine formulations, where hepatic monoamine oxidase begins acting during the absorptive phase. Pennick (2010) in Neuropsychiatric Disease and Treatment confirmed red blood cell hydrolysis as the primary conversion pathway.

Distribution: Where the Drug and Its Active Metabolite Go

Plasma Protein Binding

D-Amphetamine binds plasma proteins at roughly 15 to 40%, making it relatively free in circulation compared with many CNS drugs that exceed 90% protein binding. Lower protein binding increases the fraction available for CNS penetration but also means changes in plasma protein levels (as seen in malnutrition or liver disease) affect free-drug concentrations less dramatically than with highly bound drugs.

Volume of Distribution

The apparent volume of distribution of d-amphetamine is large. Estimates range from 3.5 to 4.6 L/kg in adults, consistent with broad tissue partitioning. Cody (1993) in the Journal of Analytical Toxicology reported comparable distribution volumes for amphetamine isomers. The drug enters the CNS efficiently because it is a small, lipophilic molecule at physiological pH, though the ionized fraction at blood pH (approximately 7.4) tempers partition compared with a fully neutral molecule.

Blood-Brain Barrier Penetration

D-Amphetamine crosses the blood-brain barrier via passive diffusion and possibly carrier-mediated transport. Cerebrospinal fluid concentrations have been measured at roughly 10 to 20% of plasma levels in animal models, a proportion consistent with its moderate lipophilicity. CNS effect durations extend well beyond the plasma half-life because intraneuronal monoamine depletion and transporter reversal persist after plasma levels fall. Volkow et al. (2001) in the American Journal of Psychiatry used PET imaging to correlate plasma amphetamine levels with striatal dopamine release.

Placental and Breast Milk Transfer

Amphetamines cross the placenta and appear in human breast milk at concentrations approximately 2 to 7 times maternal plasma levels. The FDA labels lisdexamfetamine as incompatible with breastfeeding for this reason. This is addressed in Section 8.2 of the current Vyvanse prescribing information.

Metabolism: The Conversion Step and What Happens Next

Enzymatic Hydrolysis in Red Blood Cells

The single most clinically important metabolic step is the cleavage of the amide bond between lysine and d-amphetamine. This reaction is catalyzed by peptidases present in red blood cell cytosol. The rate of this reaction is saturable at therapeutic doses, which is what creates the ceiling effect on peak d-amphetamine concentrations. When a higher oral dose of lisdexamfetamine is given, red blood cell hydrolysis does not proportionally accelerate, limiting the amplitude of the resulting amphetamine peak. Pennick (2010) in Neuropsychiatric Disease and Treatment directly measured this saturation kinetics in vitro.

Secondary Metabolic Pathways of d-Amphetamine

After d-amphetamine is liberated, it undergoes several secondary biotransformations:

• Aromatic hydroxylation to p-hydroxyamphetamine and p-hydroxynorephedrine, catalyzed partly by CYP2D6 (minor pathway).
• Beta-hydroxylation to norephedrine.
• Deamination to phenylacetone and then to benzoic acid and hippuric acid, which are excreted renally.

None of these pathways is quantitatively dominant enough to cause clinically meaningful CYP2D6 drug-drug interactions at therapeutic doses. The FDA pharmacology review for NDA 021977 addresses the CYP profile.

Urinary pH and Metabolic Rate

Urinary pH profoundly affects the relative excretion of unchanged d-amphetamine versus its metabolites. Acidic urine (pH <6.0) traps the ionized form in the renal tubule, reducing reabsorption and cutting the half-life. Alkaline urine (pH >7.4) favors reabsorption of the un-ionized form, extending the half-life. This interaction has real clinical meaning: antacids, sodium bicarbonate, and acetazolamide can prolong amphetamine effect, while ascorbic acid and ammonium chloride can shorten it. Moffat et al. Document this pH-dependent renal handling in Clarke's Analysis of Drugs and Poisons, with primary data referenced in the Vyvanse prescribing information.

Excretion: How the Body Clears Lisdexamfetamine and d-Amphetamine

Renal Excretion Dominates

In a radiolabeled mass-balance study, approximately 96% of the administered dose was recovered in urine within 120 hours. Of that urinary recovery, approximately 42% was unchanged d-amphetamine, approximately 25% was hippuric acid, approximately 2% was p-hydroxyamphetamine, and the remainder consisted of minor metabolites. Fecal excretion accounted for less than 1% of the dose. These recovery figures come from the FDA-reviewed clinical pharmacology data for lisdexamfetamine.

Half-Life of d-Amphetamine After Lisdexamfetamine Dosing

The terminal plasma half-life of d-amphetamine after lisdexamfetamine administration is approximately 10 to 13 hours in adults under normal urinary pH conditions. The half-life of intact lisdexamfetamine is much shorter, generally less than 1 hour, because conversion to d-amphetamine proceeds quickly once the prodrug reaches red blood cells. A pharmacokinetic study by Krishnan and Moncrief (2007) characterized these half-lives across multiple dose levels.

Time to Steady State

With once-daily dosing, d-amphetamine reaches steady-state plasma concentrations by day 3 to 4. The AUC at steady state is proportional to dose across the approved range of 20 mg to 70 mg daily, confirming linear pharmacokinetics within this range. Dose-proportionality was confirmed in the multiple-dose pharmacokinetic analyses submitted with NDA 021977.

Clinical Duration of Effect: What the Trials Show

Wigal et al. Published a randomized, double-blind, placebo-controlled laboratory classroom study evaluating lisdexamfetamine 30 mg, 50 mg, and 70 mg in children ages 6 to 12 with ADHD. Using the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) rating scale at 13 structured assessment points across a 13-hour day, all three doses maintained statistically significant ADHD symptom improvement from 1.5 hours through 13 hours post-dose versus placebo (P<0.001 at each time point for the 70 mg dose). Wigal et al. (J Atten Disord 2017) is indexed at PubMed PMID 26861148.

This 13-hour behavioral window substantially exceeds the duration produced by immediate-release mixed amphetamine salts, whose effects typically last 4 to 6 hours, a difference explained by the gradual rise in d-amphetamine driven by rate-limited prodrug hydrolysis.

The table below summarizes the pharmacokinetic parameters that underpin that clinical duration. Clinicians can use this framework to anticipate timing of peak effect, dose adjustments in renal impairment, and expected drug interactions.

| PK Parameter | Lisdexamfetamine (prodrug) | d-Amphetamine (active metabolite) | |---|---|---| | Tmax | ~1 hour | ~3.8 hours | | Half-life | <1 hour | 10 to 13 hours | | Protein binding | Not established | 15 to 40% | | Primary clearance | Enzymatic (RBC peptidases) | Renal (pH-dependent) | | Steady-state reached | N/A | Day 3 to 4 |

Pharmacokinetics in Special Populations

Pediatric Patients

In children ages 6 to 12, d-amphetamine AUC and Cmax after lisdexamfetamine are modestly higher per unit body weight compared with adults, primarily because of lower body weight rather than altered enzymatic activity. Dose selection in pediatrics starts at 20 to 30 mg daily and is titrated upward based on response. The pediatric pharmacokinetic data are summarized in the FDA label and supporting clinical pharmacology reviews.

A population pharmacokinetic analysis by Ermer et al. (2010) covering children, adolescents, and adults confirmed that weight-adjusted clearance of d-amphetamine was similar across these groups, supporting weight-based dose interpretation. Ermer et al. (2010) is indexed at PubMed.

Renal Impairment

Because renal excretion accounts for approximately 96% of drug recovery, kidney function directly governs clearance. The FDA label specifies a maximum dose of 50 mg daily for patients with eGFR 15 to 29 mL/min/1.73 m², and 30 mg daily for eGFR <15 mL/min/1.73 m² (including end-stage renal disease). Hemodialysis does not efficiently remove d-amphetamine given its large volume of distribution. FDA prescribing information Section 8.6 covers renal dosing.

Hepatic Impairment

Because the liver is not the primary site of prodrug conversion and d-amphetamine's secondary CYP-mediated metabolism is a minor pathway, hepatic impairment has not been shown to meaningfully alter lisdexamfetamine pharmacokinetics. No dose adjustment is recommended for hepatic impairment in the current label. This is addressed in Section 8.7 of the Vyvanse prescribing information.

Older Adults

Pharmacokinetic data in patients over 65 are limited. Age-related reductions in renal function (expected eGFR decline of approximately 1 mL/min/1.73 m² per year after age 40) increase the likelihood that older adults will require dose capping per the renal impairment guidance. The National Kidney Foundation provides reference ranges for age-adjusted eGFR norms.

Clinically Important Drug Interactions Driven by PK

Urinary Acidifying and Alkalinizing Agents

As noted above, urinary pH shifts cause the largest real-world pharmacokinetic interactions with lisdexamfetamine. Sodium bicarbonate, acetazolamide, and some antacids (particularly those containing calcium carbonate or magnesium hydroxide) alkalinize urine and can extend d-amphetamine half-life by 2 to 3 hours. Ascorbic acid in gram-level doses or ammonium chloride acidifies urine and can reduce the half-life by a similar margin, potentially causing therapeutic failure if taken habitually. The FDA prescribing information Section 7 details these interactions.

Monoamine Oxidase Inhibitors

MAO inhibitors (phenelzine, tranylcypromine, selegiline, linezolid, methylene blue) block the deamination pathway of d-amphetamine and can precipitate hypertensive crisis or serotonin syndrome. Lisdexamfetamine is contraindicated within 14 days of MAOI use. This contraindication aligns with pharmacokinetic reasoning and is listed in Section 4 of the Vyvanse prescribing information.

Serotonergic Agents

Co-administration with SSRIs, SNRIs, triptans, or fentanyl raises the theoretical risk of serotonin syndrome because d-amphetamine itself increases synaptic serotonin through SERT reversal at higher concentrations. Roth et al. (2004) in Psychopharmacology characterized amphetamine's serotonin transporter activity.

CYP2D6 Inhibitors

Fluoxetine, paroxetine, and bupropion inhibit CYP2D6, which handles the minor aromatic hydroxylation pathway of d-amphetamine. The clinical magnitude of this interaction is generally small at therapeutic doses, but may be relevant in poor metabolizers already carrying loss-of-function CYP2D6 alleles. The FDA drug interaction guidance for stimulants addresses this in the label.

Comparing Lisdexamfetamine PK to Other ADHD Stimulants

Versus Immediate-Release Amphetamine

Immediate-release amphetamine salts (Adderall) reach peak plasma d-amphetamine levels within 1 to 2 hours and produce a rapid descending concentration curve thereafter, with clinical effects lasting 4 to 6 hours. The sharp Cmax is associated with greater euphoria perception and higher abuse potential scores on subjective rating scales. Lisdexamfetamine's Tmax of 3.8 hours and the blunted Cmax are direct consequences of red blood cell conversion kinetics. Jasinski and Krishnan (2009) compared abuse potential scores directly in a randomized crossover design.

Versus Extended-Release Methylphenidate

Extended-release methylphenidate (Concerta, OROS formulation) uses a mechanical osmotic pump to deliver methylphenidate over approximately 8 to 10 hours, producing a different PK profile. Methylphenidate acts by blocking DAT and NET rather than reversing them, which means its pharmacodynamic ceiling differs from amphetamine's. Head-to-head pharmacokinetic comparisons are not directly applicable because the drugs act at different receptor sites, but meta-analytic data suggest lisdexamfetamine produces larger effect sizes for ADHD core symptoms. Cortese et al. (2018) in Lancet Psychiatry conducted a network meta-analysis of 133 randomized trials covering 10,068 children and 8,131 adults.

Versus Atomoxetine

Atomoxetine (Strattera) is a non-stimulant NET inhibitor with a half-life of 5 hours in extensive CYP2D6 metabolizers and 21 hours in poor metabolizers. Its pharmacokinetics are driven heavily by CYP2D6 genotype, making it far more susceptible to CYP2D6 drug-drug interactions than lisdexamfetamine. Onset of therapeutic effect takes 4 to 8 weeks versus the same-day response seen with lisdexamfetamine. Sauer et al. (2005) in the Journal of Clinical Pharmacology characterized atomoxetine CYP2D6 pharmacogenomics.

PK-Based Prescribing Decisions Clinicians Make Daily

Timing the Morning Dose

Given a Tmax for d-amphetamine of 3.8 hours, a patient taking lisdexamfetamine at 7:00 AM reaches peak plasma concentrations around 10:45 AM. That aligns with mid-morning work or school demands. Patients who report wearing off by 3:00 PM may actually be experiencing the descending limb of a lower-dose exposure rather than a true short-duration response. A dose increase (up to 70 mg) may extend the tail, because higher doses produce proportionally higher AUC without proportionally higher Cmax due to saturation of red blood cell hydrolysis.

When to Consider a Dose Cap for Renal Patients

A patient with an eGFR of 20 mL/min/1.73 m² has roughly a 40 to 50% reduction in d-amphetamine clearance compared with a healthy adult. Without dose reduction, the steady-state Cmax and AUC will accumulate beyond the therapeutic window, raising cardiovascular risk. The label-specified 30 mg daily maximum in this group is grounded directly in the renal excretion data showing 96% urinary recovery. FDA Section 8.6 of the Vyvanse prescribing information.

Interpreting Urine Drug Screens

Standard urine immunoassay screens for amphetamines detect d-amphetamine. A patient prescribed lisdexamfetamine 70 mg daily will test positive for amphetamines, with urinary concentrations peaking 4 to 6 hours after ingestion and remaining above typical cut-off thresholds (300 to 500 ng/mL) for 2 to 4 days depending on urinary pH. Clinicians should document the prescription to contextualize workplace or probation drug screen results. The SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing detail amphetamine cut-off thresholds.